Compare $ALGS vs $RNAZ | Chartloom

Compare

$ALGS vs $RNAZ

Aligos Therapeutics Inc · Transcode Therapeutics Inc

ALGS

Aligos Therapeutics Inc

RNAZ

Transcode Therapeutics Inc

Compare $ALGS vs $RNAZ

Comparing Aligos Therapeutics Inc and Transcode Therapeutics Inc

ALGSAligos Therapeutics Inc

RNAZTranscode Therapeutics Inc

ALGSAligos Therapeutics Inc

Market cap

$33M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

4.83x

Rev growth (TTM)

893.0%

YTD performance

-41.5%

52W performance

-46.2%

FCF yield

-286.0%

RNAZTranscode Therapeutics Inc

Market cap

$2M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-74.9%

52W performance

-82.4%

FCF yield

-1146.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ALGS

RNAZ

Detailed metrics comparison

ALGS

Aligos Therapeutics Inc

RNAZ

Transcode Therapeutics Inc

Market Cap

ALGS$33M

RNAZ$2M

Enterprise Value

ALGS$3M

RNAZ$-6M

Price

ALGS$5.34

RNAZ$1.86

P/E Ratio

ALGSN/A

RNAZN/A

P/S Ratio

ALGS1.05x

RNAZ0.00x

EV/Sales

ALGS0.09x

RNAZ0.00x

EV/EBITDA

ALGS0.00x

RNAZ0.00x

P/B Ratio

ALGS1.09x

RNAZ0.19x

P/FCF Ratio

ALGSN/A

RNAZN/A

EV/FCF

ALGS-0.03x

RNAZ0.25x

PEG Ratio

ALGSN/A

RNAZN/A

Forward P/E (NTM)

ALGSN/A

RNAZN/A

Forward P/S (NTM)

ALGS4.83x

RNAZN/A

Revenue (TTM)

ALGS$32M

RNAZ$0

Revenue Growth (YoY)

ALGS893.0%

RNAZN/A

Forward Rev Growth

ALGS-84.9%

RNAZ0.0%

Gross Margin (TTM)

ALGS0.0%

RNAZ0.0%

Operating Margin (TTM)

ALGS0.0%

RNAZ0.0%

EBITDA Margin (TTM)

ALGS-247.2%

RNAZ0.0%

Net Margin (TTM)

ALGS-241.0%

RNAZ0.0%

FCF Margin (TTM)

ALGS-299.9%

RNAZN/A

Net Income (TTM)

ALGS$-76M

RNAZ$-46M

FCF (TTM)

ALGS$-95M

RNAZ$-23M

EPS (TTM)

ALGS-$7.28

RNAZ-$48.35

ROE (TTM)

ALGS-16072.0%

RNAZ-3928.0%

ROA (TTM)

ALGS-9230.0%

RNAZ-3601.0%

ROIC (TTM)

ALGS-16035.0%

RNAZ-3922.0%

Cash

ALGS$30M

RNAZ$8M

Debt

ALGS$64K

RNAZ$652K

Net Cash/Debt

ALGS$30M

RNAZ$8M

Current Ratio (TTM)

ALGS2.19x

RNAZ1.97x

Quick Ratio (TTM)

ALGS2.19x

RNAZ1.55x

Debt/Equity (TTM)

ALGS0.00x

RNAZ0.00x

Debt/Assets (TTM)

ALGS0.0%

RNAZ0.0%

Interest Coverage (TTM)

ALGSN/A

RNAZN/A

Net Debt/EBITDA (TTM)

ALGS0.00x

RNAZ0.00x

Beta

ALGS2.48

RNAZ1.29

52W Performance

ALGS-46.2%

RNAZ-82.4%

YTD Performance

ALGS-41.5%

RNAZ-74.9%

% from 52W High

ALGS-61.0%

RNAZ-91.1%

% from 52W Low

ALGS34.2%

RNAZ22.4%

Asset Turnover (TTM)

ALGS0.38x

RNAZ0.00x

FCF Yield (TTM)

ALGS-286.0%

RNAZ-1146.9%

Earnings Yield (TTM)

ALGS-229.8%

RNAZ-2347.6%

Dividend Yield (TTM)

ALGSN/A

RNAZN/A

Rule of 40

ALGS593.1

RNAZ0.0

EV/GP/RG

ALGSN/A

RNAZN/A

Ticker research

View ALGS research View RNAZ research

Metric	ALGS Aligos Therapeutics Inc	RNAZ Transcode Therapeutics Inc
Market & Valuation
Market Cap	$33M	$2M
Enterprise Value	$3M	$-6M
Price	$5.34	$1.86
P/E Ratio	N/A	N/A
P/S Ratio	1.05x	0.00x
EV/Sales	0.09x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.09x	0.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.03x	0.25x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.83x	N/A
Revenue & Growth
Revenue (TTM)	$32M	$0
Revenue Growth (YoY)	893.0%	N/A
Forward Rev Growth	-84.9%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-247.2%	0.0%
Net Margin (TTM)	-241.0%	0.0%
FCF Margin (TTM)	-299.9%	N/A
Net Income (TTM)	$-76M	$-46M
FCF (TTM)	$-95M	$-23M
EPS (TTM)	-$7.28	-$48.35
ROE (TTM)	-16072.0%	-3928.0%
ROA (TTM)	-9230.0%	-3601.0%
ROIC (TTM)	-16035.0%	-3922.0%
Financial Health
Cash	$30M	$8M
Debt	$64K	$652K
Net Cash/Debt	$30M	$8M
Current Ratio (TTM)	2.19x	1.97x
Quick Ratio (TTM)	2.19x	1.55x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.48	1.29
52W Performance	-46.2%	-82.4%
YTD Performance	-41.5%	-74.9%
% from 52W High	-61.0%	-91.1%
% from 52W Low	34.2%	22.4%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.00x
FCF Yield (TTM)	-286.0%	-1146.9%
Earnings Yield (TTM)	-229.8%	-2347.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	593.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ALGS research	View RNAZ research

Valuation

P/S Ratio

RNAZ

0.00x

ALGS

1.05x

EV/FCF

ALGS

-0.03x

RNAZ

0.25x

Growth & revenue

Revenue Growth TTM

ALGS

893.0%

Forward Revenue Growth

RNAZ

0.0%

ALGS

-84.9%

Profitability & performance

Gross Margin

ALGS

0.0%

RNAZ

0.0%

ROE

RNAZ

-3928.0%

ALGS

-16072.0%

FCF Yield %

ALGS

-286.0%

RNAZ

-1146.9%

52-Week Performance

ALGS

-46.2%

RNAZ

-82.4%

Detailed metrics comparison

ALGS

Aligos Therapeutics Inc

RNAZ

Transcode Therapeutics Inc

Market Cap

ALGS$33M

RNAZ$2M

Enterprise Value

ALGS$3M

RNAZ$-6M

Price

ALGS$5.34

RNAZ$1.86

P/E Ratio

ALGSN/A

RNAZN/A

P/S Ratio

ALGS1.05x

RNAZ0.00x

EV/Sales

ALGS0.09x

RNAZ0.00x

EV/EBITDA

ALGS0.00x

RNAZ0.00x

P/B Ratio

ALGS1.09x

RNAZ0.19x

P/FCF Ratio

ALGSN/A

RNAZN/A

EV/FCF

ALGS-0.03x

RNAZ0.25x

PEG Ratio

ALGSN/A

RNAZN/A

Forward P/E (NTM)

ALGSN/A

RNAZN/A

Forward P/S (NTM)

ALGS4.83x

RNAZN/A

Revenue (TTM)

ALGS$32M

RNAZ$0

Revenue Growth (YoY)

ALGS893.0%

RNAZN/A

Forward Rev Growth

ALGS-84.9%

RNAZ0.0%

Gross Margin (TTM)

ALGS0.0%

RNAZ0.0%

Operating Margin (TTM)

ALGS0.0%

RNAZ0.0%

EBITDA Margin (TTM)

ALGS-247.2%

RNAZ0.0%

Net Margin (TTM)

ALGS-241.0%

RNAZ0.0%

FCF Margin (TTM)

ALGS-299.9%

RNAZN/A

Net Income (TTM)

ALGS$-76M

RNAZ$-46M

FCF (TTM)

ALGS$-95M

RNAZ$-23M

EPS (TTM)

ALGS-$7.28

RNAZ-$48.35

ROE (TTM)

ALGS-16072.0%

RNAZ-3928.0%

ROA (TTM)

ALGS-9230.0%

RNAZ-3601.0%

ROIC (TTM)

ALGS-16035.0%

RNAZ-3922.0%

Cash

ALGS$30M

RNAZ$8M

Debt

ALGS$64K

RNAZ$652K

Net Cash/Debt

ALGS$30M

RNAZ$8M

Current Ratio (TTM)

ALGS2.19x

RNAZ1.97x

Quick Ratio (TTM)

ALGS2.19x

RNAZ1.55x

Debt/Equity (TTM)

ALGS0.00x

RNAZ0.00x

Debt/Assets (TTM)

ALGS0.0%

RNAZ0.0%

Interest Coverage (TTM)

ALGSN/A

RNAZN/A

Net Debt/EBITDA (TTM)

ALGS0.00x

RNAZ0.00x

Beta

ALGS2.48

RNAZ1.29

52W Performance

ALGS-46.2%

RNAZ-82.4%

YTD Performance

ALGS-41.5%

RNAZ-74.9%

% from 52W High

ALGS-61.0%

RNAZ-91.1%

% from 52W Low

ALGS34.2%

RNAZ22.4%

Asset Turnover (TTM)

ALGS0.38x

RNAZ0.00x

FCF Yield (TTM)

ALGS-286.0%

RNAZ-1146.9%

Earnings Yield (TTM)

ALGS-229.8%

RNAZ-2347.6%

Dividend Yield (TTM)

ALGSN/A

RNAZN/A

Rule of 40

ALGS593.1

RNAZ0.0

EV/GP/RG

ALGSN/A

RNAZN/A

Ticker research

View ALGS research View RNAZ research

Metric	ALGS Aligos Therapeutics Inc	RNAZ Transcode Therapeutics Inc
Market & Valuation
Market Cap	$33M	$2M
Enterprise Value	$3M	$-6M
Price	$5.34	$1.86
P/E Ratio	N/A	N/A
P/S Ratio	1.05x	0.00x
EV/Sales	0.09x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.09x	0.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.03x	0.25x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.83x	N/A
Revenue & Growth
Revenue (TTM)	$32M	$0
Revenue Growth (YoY)	893.0%	N/A
Forward Rev Growth	-84.9%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-247.2%	0.0%
Net Margin (TTM)	-241.0%	0.0%
FCF Margin (TTM)	-299.9%	N/A
Net Income (TTM)	$-76M	$-46M
FCF (TTM)	$-95M	$-23M
EPS (TTM)	-$7.28	-$48.35
ROE (TTM)	-16072.0%	-3928.0%
ROA (TTM)	-9230.0%	-3601.0%
ROIC (TTM)	-16035.0%	-3922.0%
Financial Health
Cash	$30M	$8M
Debt	$64K	$652K
Net Cash/Debt	$30M	$8M
Current Ratio (TTM)	2.19x	1.97x
Quick Ratio (TTM)	2.19x	1.55x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.48	1.29
52W Performance	-46.2%	-82.4%
YTD Performance	-41.5%	-74.9%
% from 52W High	-61.0%	-91.1%
% from 52W Low	34.2%	22.4%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.00x
FCF Yield (TTM)	-286.0%	-1146.9%
Earnings Yield (TTM)	-229.8%	-2347.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	593.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ALGS research	View RNAZ research